Programme – 3rd Scientific Summit

Download the Final Programme in pdf format.
Click on the presentation / session title to watch the video.

Select a timezone:
Athens, Greece (EEST) Brussels, Belgium (CEST) Sao Paolo, Brazil (GMT-3) Singapore / Beijing (GMT+8)

9:30-11:00	Novel nicotine-delivering products: toxicology, regulation, and health issues Chairs: Demetrios Kouretas & Konstantinos Poulas – Systems toxicology assessment of a representative e-liquid formulation using human primary bronchial epithelial cells, Diego Marescotti – The flavoring and not the nicotine content of e-cigarette refill liquids affects the redox status of endothelial cells, Zoi Skaperda – Smokeless tobacco induced biophysical and biochemical alterations in the plasma, erythrocytes, and platelets of panmasala users: subsequent biological effects, Narendra Maddu – Reductions in biomarkers of exposure when switching from cigarette smoking to using a tobacco heating product for 6 months, Nathan Gale – Toxicity assessment of a range of flavour eliquids, Damien Breheny
11:00-11:30	Opening remarks Goals of the 3rd Scientific Summit on Tobacco Harm Reduction Organizing Committee
11:30-13:00	Tobacco Control Policies – Do they work? Chairs: Michael G. Toumbis & Karl E. Lund – Global tobacco control efforts — What has been done so far? Stamatoula Tsikrika – How are we addressing youth appeal and access? Lion Shahab – Smoking Cessation: Best practices to improve quit rates, Georgios S. Goumas – e-Cigarettes for smoking cessation, Paraskevi A. Katsaounou
13:00-14:30	Oral Presentations (submitted abstracts) Chairs: Anastasia Barbouni, Konstantinos Poulas, Demetrios Kouretas Epidemiology & Social Issues IQOS uptake and history of tobacco product use: findings from cross-sectional surveys in Japan, Italy, and Germany, Steve Roulet Estimates of the population’s use of the JUUL Electronic Nicotine Delivery System may vary between survey questions that are accompanied and unaccompanied by an image of the JUUL device, Christopher Russell Smoking cessation Understanding the need to (re) innovate Tobacco Harm Reduction strategies for the Indian subcontinent, Nilesh Jain Clinical Assessment and Harm Reduction Tobacco Heating System 2.2 in mild to moderate chronic obstructive pulmonary disease subjects: An exploratory analysis, Francesco Sergio
14:30-15:00	Break \|\| Posters Q & A (I) Thematic categories: 1 – Epidemiology & Social Issues (perception risk, attractiveness, etc.) 2 – Toxicology and aerosol chemistry etc 3 – Biomarkers’ evaluation in animal or human studies 4 – Preclinical evaluation
15:00-15:30	Keynote lecture Risk proportionate regulation and the science to support it: How rapidly can we end the epidemic of cigarette-caused disease? David T. Sweanor J.D. Chair: Ignatios Ikonomidis
15:30-17:00	Public Health Policy and Regulation – What is expected in the future? Chairs: Panos E. Vardas & David T. Sweanor J.D. – Longitudinal evaluation of Harm Reduction strategies worldwide, Karl Fagerström – What standards should authorities apply to alternative nicotine products to address challenges without losing potential benefits to adult smokers? Michael G. Toumbis – Public health risk communication: the FDA example, Clive Bates
17:00-18:30	Clinical Assessment and Research Chairs: Peter Harper & Ignatios Ikonomidis – Update on e-cigarettes publications: Safety and effects on smokers, nonsmokers and youth, Konstantinos Farsalinos – Potential to reduce the risk of smoking-related diseases when switching from smoking to the tobacco heating system, Christelle Haziza – Acute effects of heat-not-burn versus standard cigarette smoking in smokers, Charalambos Vlachopoulos – Novel smoking products and cardiovascular risk, Giuseppe Biondi Zoccai – Differential effects of heat-not-burn and conventional cigarettes on coronary flow, myocardial and vascular function, John Thymis

9:30-10:00	Hot topic COVID-19 and nicotinic cholinergic system: an interaction which affects Public Health, Konstantinos Poulas & Konstantinos Farsalinos
10:00-10:30	Keynote lecture Could the scientific and medical community play a role in making policy makers to reconsider the tobacco control strategies? David Khayat Chair: Demetrios Kouretas
10:30-11:00	Lecture New Legislation on smoking control in Greece, Ioannis Faropoulos Chair: Anastasia Barbouni
11:00-12:30	Panel Discussion Should Tobacco Harm Reduction become a Public Health Policy tool globally? Chair: Panos E. Vardas Panelists: Ladislav Czemy, Stanimir Hasardzhiev, Karl Fagerstrom, Andrzej M. Fal, Fernando Fernandez Bueno, Charmaine Gauci, Karl E. Lund, Alex Wodak
12:30-13:30	Panel Discussion The doctor’s dilemma: Providing guidance on alternative smoking products to adult smokers amid controversy and change Chair: Dimitri Richter Panelists: Efrain Cambronero, Manuel Pais Clemente, Peter Harper, Piotr Kuna, Emil Toldy-Schedel, Michael G. Toumbis
13:30-14:00	Break \|\| Posters Q & A (II) Thematic categories: 5 – Regulatory issues 6 – Smoking cessation 7 – Clinical Assessment and Harm Reduction
14:00-15:00	Panel Discussion Tobacco Harm Reduction in low- and middle-income countries Chair: Nimesh G. Desai Panelists: Amaliya Amaliya, Efrain Cambronero, Sharifa Ezat Wan Puteh, Kgosi Letlape, Fares Mili, Rajesh Sharan, Ron Christian G. Sison
15:00-16:00	Panel Discussion Bioethics: Smokers right on credible information Chair: Konstantinos Farsalinos Panelists: Panagiotis D. Bamidis, Stanimir Hasardzhiev, Monica Gorgulho, Enrique Rios Espinosa
16:00-17:00	Smoking Control & Harm Reduction Association Announcement – Mission, Values, Principles – Position Statement & Voting
17:00-17:30	Closing Remarks Organizing Committee